Open access
Sep 2026
Aptamer-guided delivery of miR-126 suppresses glioblastoma stem-like cell invasion and tumor progression
Glioblastoma, IDH-wildtype (GBM) is the most common and aggressive primary brain tumor in adults, with a median overall survival of 15–18 months. New therapeutic targets are needed to improve patients’ prognosis. Due to their powerful regulatory capabilities, miRNAs could be possible candidate targets. MiR-126 is consi...
G. Castellani, M. Buccarelli, A. Affinito et al.
· Molecular Therapy: Nucleic A... · 0 citations